Article info
Original research
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
- Correspondence to Dr Sarah Betrian, Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse, Toulouse 31100, France; betrian.sarah{at}iuct-oncopole.fr
Citation
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
Publication history
- Received January 3, 2022
- Accepted May 31, 2022
- First published July 20, 2022.
Online issue publication
August 01, 2022
Article Versions
- Previous version (20 July 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.